Johnson & Johnson (JNJ) Long-Term Deferred Tax (2009 - 2026)
Johnson & Johnson (JNJ) posted Long-Term Deferred Tax of $6.7 billion for Q1 2026, down 2.14% sequentially from $6.9 billion in Q4 2025, and down 20.78% YoY from $8.5 billion in Q1 2025.
Johnson & Johnson (JNJ) Long-Term Deferred Tax (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Long-Term Deferred Tax data on file, last reported at $6.7 billion in Q1 2026.
- Quarterly Long-Term Deferred Tax fell 20.78% year-over-year to $6.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 billion (down 20.78% YoY) and the FY2025 annual result came in at $6.9 billion, down 34.29% from the prior year.
- Long-Term Deferred Tax eased to $6.7 billion in Q1 2026 per JNJ's latest filing, from $6.9 billion in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $10.5 billion in Q4 2024, with the low at $6.7 billion in Q3 2025.
- Average Long-Term Deferred Tax over 5 years is $8.8 billion, with a median of $9.1 billion recorded in 2023.
- Year-over-year, Long-Term Deferred Tax advanced 19.79% in 2022 and sank 34.29% in 2025.
- Johnson & Johnson's Long-Term Deferred Tax stood at $9.4 billion in 2022, then declined by 1.2% to $9.3 billion in 2023, then advanced by 12.74% to $10.5 billion in 2024, then slumped by 34.29% to $6.9 billion in 2025, then slipped by 2.14% to $6.7 billion in 2026.
- Business Quant data shows JNJ's Long-Term Deferred Tax at $6.7 billion in Q1 2026, $6.9 billion in Q4 2025, and $6.7 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 6.73 Bn |
| Dec 28, 2025 | 6.87 Bn |
| Sep 28, 2025 | 6.67 Bn |
| Jun 29, 2025 | 6.80 Bn |
| Mar 30, 2025 | 8.49 Bn |
| Dec 29, 2024 | 10.46 Bn |
| Sep 29, 2024 | 9.35 Bn |
| Jun 30, 2024 | 9.00 Bn |
| Mar 31, 2024 | 10.31 Bn |
| Dec 31, 2023 | 9.28 Bn |
| Oct 1, 2023 | 9.26 Bn |
| Jul 2, 2023 | 8.78 Bn |
| Apr 2, 2023 | 8.82 Bn |
| Jan 1, 2023 | 8.95 Bn |
| Oct 2, 2022 | 9.39 Bn |
| Jul 3, 2022 | 9.51 Bn |
| Apr 3, 2022 | 9.94 Bn |
| Jan 2, 2022 | 10.22 Bn |
| Oct 3, 2021 | 10.65 Bn |
| Jul 4, 2021 | 10.80 Bn |